Company Profile for EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company’s broad portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is approaching a decision in Europe. In addition, EpiCept’s ASAP technology, a proprietary live cell high-throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.
Company:
EpiCept Corporation
Headquarters Address:
777 Old Saw Mill River Road
Tarrytown, NY 10591
Main Telephone:
914-606-3500
Website:
www.epicept.com
Ticker/ISIN:
EPCT(NASDAQ)/US2942642057
EPCT(STO)/US2942642057
Type of Organization:
Public
IRPR
Industry:
Pharmaceutical
Key Executives:
CFO: Robert W. Cook
CEO: Jack V. Talley
Investor Relations
Contact:
Kim Sutton-Golodetz
Phone:
212-838-3777
Email:
kgolodetz@lhai.com
Investor Relations
Contact:
Bruce Voss
Phone:
310-691-7100
Email:
bvoss@lhai.com
Public Relations
Contact:
Gregory Kelley
Phone:
617-577-8110
Email:
gregory.kelley@fkhealth.com